



**Business Plan for Production** of Azithromycin, Cefixime, Telmisartan, Diclofenac Sodium, Acecloflenac Active Pharma Ingredients (API)

Manufacturing













www.niir.org



# Introduction

An active ingredient is that the ingredient during a pharmaceutical drug or pesticide that's biologically active. The similar terms active pharmaceutical ingredient and bulk active also are utilized in medicine, and therefore the term active substance could also be used for natural products. Some medication products may contain more than one active ingredient. The normal word for the active pharmaceutical agent is pharma con or pharm Akon which originally denoted a magical substance or drug.

Related Project: - <u>Active Pharma Ingredients • Azithromycin • Cefixime</u>

• Telmisartan • Diclofenac Sodium • Acecloflenac





The terms active constituent or active principle are often chosen when pertaining to the active substance of interest during a plant (such as 2-hydroxybenzoic acid in willow bark or are choline in areca nuts), because the word ingredient in many minds connotes a way of human agency (that is, something that an individual combines with other substances), whereas the natural products present in plants weren't added by any human agency but rather occurred naturally ("a plant doesn't have ingredients").

Related Projects: - Active Pharmaceutical Ingredient (API) Products,

#### **Bulk API Manufacturing**





Azithromycin is an antibiotic used for the treatment of variety of bacterial infections. This includes middle ear infections, streptococcus tonsillitis, pneumonia, traveler's diarrhea, and certain other intestinal infections. It also can be used for variety of sexually transmitted infections, including chlamydia and gonorrhea infections. Alongside other medications, it's going to even be used for malaria. It are often taken by mouth or intravenously with doses once per day.

Cefixime, an antibiotic, may be a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is very stable within the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and a few cephalosporins because of the presence of beta-lactamases, could also be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis within the bacterial cell wall.



Cefixime, sold under the brand name Surtax among others, is an antibiotic medication won't to treat variety of bacterial infections. These infections include otitis, strep throat, pneumonia, tract infections, gonorrhea, and lyme disease. For gonorrhea typically just one dose is required. Within the us it's a second-line treatment to ceftriaxone for gonorrhea. It's taken by mouth.

Related Books: - Pharmaceutical, Drugs, Proteins Technology

#### **Handbooks**

Telmisartan, sold under the brand name Micardis among others, may be a medication used to treat high blood pressure, heart failure, and diabetic renal disorder. It's an inexpensive initial treatment for top blood pressure. It's taken orally. Versions are available because the combination telmisartan/hydrochlorothiazide and telmisartan / amlodipine.



Diclofenac, sold under the name Voltaren among others, may be a nonsteroidal anti-inflammatory drug (NSAID) wont to treat pain and inflammatory diseases like gout. It's taken by mouth, rectally during a suppository, employed by injection, or applied to the skin. Improvements in pain last for the maximum amount as eight hours. It's also available in combination with misoprostol in an effort to decrease stomach problems. Aceclofenac may be a nonsteroidal anti-inflammatory drug (NSAID) analog of diclofenac. It's used for the relief of pain and inflammation in rheumatoid arthritis, osteoarthritis and ankylosing spondylitis.

Related Project: - Active Pharma Ingredients • Azithromycin • Cefixime •

<u>Telmisartan • Diclofenac Sodium • Acecloflenac</u>





#### Role of Government towards API

The coronavirus outbreak disrupting supply of <u>active pharmaceutical</u> <u>ingredients</u> (APIs) and medical devices from China to <u>India</u>, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk <u>drugs</u> and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively.

Related Videos: - <u>Pharmaceutical</u>, <u>Drugs</u>, <u>Fine Chemicals</u>, <u>Bulk Drugs</u>

<u>Intermediates</u>, <u>Pharmaceutical Drugs</u>, <u>Pharma Drug Ingredients</u>

<u>Intermediates</u>, <u>Pharmaceutical Bulk Drugs</u>





The Cabinet also approved a scheme on promotion of bulk <u>drug</u> parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk <u>Drug</u> Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc.

The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years.

Financial incentive will be given to eligible manufacturers of identified 53 critical <u>bulk drugs</u> on their incremental sales over the base year (2019-20) for a period of 6 years.



Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are <u>chemical</u> synthesis based bulk drugs.

Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for <u>chemical</u> synthesis based bulk drugs.

The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years.

The drug industry has welcomed the incentives offered by the government to promote API units in <u>India</u>.

Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore.



The PLI scheme for promoting domestic manufacturing of <u>medical</u> devices will have financial implications of Rs. 3,420 crore for next five years.

Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices.

**Projects: - Project Reports & Profiles** 





#### <u>Union Cabinet scheme on Promotion of Bulk Drug Parks</u>

- The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years.
- Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/<u>Drug</u> Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years.

**Projects: - Project Reports & Profiles** 





#### **Details:**

Promotion of Bulk Drug Parks

- Decision is to develop 3 mega <u>Bulk Drug</u> parks in India in partnership with States.
- Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park.
- Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc.
- A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years.

**Books: - Books & Databases** 



#### **Production Linked Incentive Scheme**

- Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years.
- Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are <u>chemical</u> synthesis based bulk drugs.
- Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for <u>chemical</u> synthesis based bulk drugs.
- A sum of Rs. 6,940 crore has been approved for next 8 years.

Market Research Reports: - <u>Market Research Reports, India and Global Industry</u>

<u>Analysis, Market Trends</u>





#### **Market Outlook**

Active pharmaceutical ingredients are an active ingredient of any drug or tablet, which possesses medicinal properties. Some drugs with combined therapy have many active ingredients to treat different disorders. The increasing occurrences of chronic diseases, growth in abbreviated new drug applications (ANDA), rising acceptance and uptake of biopharmaceuticals, and the growing importance of generics across the globe is expected to enhance the Active Pharmaceutical Ingredients Market growth. However, the stringent regulatory policies and adverse drug price control policies across numerous countries are likely to curb the growth of the market.

**Projects:** - **Project Reports & Profiles** 





The API market is surging due to the increased demand for pharmaceutical drugs, which in turn is driven by the aging population, rising prevalence of chronic diseases such as cancer, diabetes, cardiovascular, neurological and infectious diseases. India and China are the major suppliers of APIs to North America due to their low production capacities, labor costs and the presence of a large number of global and domestic players. In order to cut down on expenses and increase profits, companies have begun outsourcing the creation of APIs to the developing countries in Asia, leading to growth in the Asian market.

**Books: - Books & Databases** 





Rise in demand for new drugs at a low cost and entry of domestic and global companies in the APIs market have led to innovative product offerings with new and advanced techniques. Any substance or combination of substances used in a finished pharmaceutical product (FPP) is known as active pharmaceutical ingredients (API). High-potency active <u>pharmaceutical</u> ingredients (HPAPIs) and antibody-drug conjugates are recent innovations in the market and require a special manufacturing set up. Most of these drugs are used in oncology. A large number of patents for small molecule APIs are expected to expire in the next few years, with many drugs losing patent protection in 2018. This is estimates to unlock a significant market opportunity for generic drug manufacturers, resulting in augmented demand for APIs.

**Projects: - Project Reports & Profiles** 



### **Higher Growth**

Healthcare spending has witnessed continued growth for some time now. Even though the proportion of healthcare spending in the APAC region is comparatively low, the growth rate in this strategic region has outpaced that of mature markets in North America and Europe. Rising healthcare spending has led to quality healthcare becoming accessible along with a higher demand for pharmaceutical products across APAC. The <u>pharmaceuticals</u> consumed here are mostly produced in onshore manufacturing units. Furthermore, contract manufacturing organizations are key outsourcing allies for pharmaceutical companies that supply their wares to North America and Europe.

**Projects: - Project Reports & Profiles** 





### **Market Segmentations**

- ❖ Based on manufacturing process, the Global Active Pharmaceutical Ingredients Market has been segmented into captive manufacturing and contract manufacturing.
- ❖ Based on type of synthesis, the Global Active Pharmaceutical Ingredients Market has been segmented into synthetic and biotech. On the basis of biotech synthesis, the market is further sub-segmented into monoclonal antibodies, recombinant proteins, vaccines, and others.
- ❖ Based on API formulation, the Global Active Pharmaceutical Ingredients

  Market has been divided into generic API and branded / innovative API.

Market Research Reports: - <u>Market Research Reports</u>, <u>India and Global Industry Analysis</u>, <u>Market Trends</u>



- ❖ Based on application, the global market is segmented into cardiovascular disease oncology, neurological disorders, orthopedic disorders, respiratory, gastrointestinal disorders, urology, and others.
- ❖ Based on molecule, the global Active Pharmaceutical Ingredients Market is divided into large molecule and small molecule.

Related Project: - Active Pharma Ingredients • Azithromycin • Cefixime •

<u>Telmisartan • Diclofenac Sodium • Acecloflenac</u>



#### Global Active Pharmaceutical Ingredient Market Dynamics

The key factor for growth of worldwide Active Pharmaceutical Ingredient market is that the rise of demand for the new drug discovery for treatment of various chronic and infectious diseases like HIV, cancer, arthritis, bone & joint infections, hepatitis-B, Aids etc. across the world. According to WHO in 2018, the worldwide cancer burden has risen to 18.1 million new cases including 9.6 million deaths across the world. Because of such rise within cases of cancer, the new drugs discovery using the Active Pharmaceutical Ingredient has become essential. Recently consistent with the American Chemical Society in 2019, there has been 48 new drugs has been approved by the FDA U.S. out of which 11 for brand new cancer treatments with the innovative molecular pharmaceutical ingredients.



However, the <u>Active Pharmaceutical Ingredient</u> market is hampered by need for prime investment with huge capital requirement for research and developments. Moreover rising health cautiousness among the people with technological advancement huge investment for launching of recent drugs and biological products, acquisitions, collaborations, and regional expansion will provide huge opportunity for <u>Active Pharmaceutical Ingredient</u> market.

Active Pharmaceutical Ingredients are chemically and biologically active components of medicine with direct effect in cure, mitigation, treatment and prevention of diseases. The worldwide API market has witnessed tremendous growth over the previous couple of decades because of the increased use of medicine and biologics within the treatment of diseases.





On the opposite hand, the API industry is facing the challenges such as, shortening the event time, reducing the value of development, improving the method design and meeting the standard without compromising on the profitability. The worldwide API market is probably going to be impacted by an outsized number of innovative drugs going off patent within the recent years. There's an impending need for technological innovations to take care of the profitability in high volume and a coffee value environment. the most important factors driving the market growth are, rising incidences of oncology, cardiovascular, diabetes and lifestyle diseases, rising number of hospitals and diagnostic centers, rising geriatric population in developing countries, increasing healthcare expenditure, increasing disease awareness and education. However, a scarcity of skilled workforce and limited accessibility of medicine within the developing countries are likely to restrict the market growth.



The global <u>active pharmaceutical ingredient</u> market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years.

Market Research Reports: - <u>Market Research Reports</u>, <u>India and Global</u>
<u>Industry Analysis</u>, <u>Market Trends</u>



### **Key Players:-**

- > Alpha Remedies Ltd.
- > Ankur Drugs & Pharma Ltd.
- > Aurobindo Pharma Ltd.
- > Cian Healthcare Ltd
- > Cipla Ltd.
- > Dr. Reddy'S Laboratories Ltd.
- > Farmson Pharmaceutical Gujarat Pvt. Ltd.
- > Glaxosmithkline Pharmaceuticals Ltd.
- > Indoco Remedies Ltd.
- > Pan Drugs Ltd.



- Piramal Enterprises Ltd.
- > Sanofi India Ltd.
- > Sri Krishna Pharmaceuticals Ltd.
- > Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.
- > Triton Laboratories Ltd.



# **Machinery Photographs**



Jacketed Reactor




Filter





Fluidised Bed Dryer



**Distillation Assembly** 

#### www.niir.org

# **Project at a Glance**

COST	OF PROJE	CCT		MEANS	OF FINAL	NCE	
						Propose	
Particulars	Existing	Proposed	Total	Particulars	Existing	d	Total
Land & Site							
Development Exp.	0.00	10.00	10.00	Capital	0.00	182.20	182.20
Buildings	0.00	162.70	162.70	Share Premium	0.00	0.00	0.00
				Other Type Share			
Plant & Machineries	0.00	155.10	155.10	Capital	0.00	0.00	0.00
Motor Vehicles	0.00	8.00	8.00	Reserves & Surplus	0.00	0.00	0.00
Office Automation							
Equipments	0.00	39.00	39.00	Cash Subsidy	0.00	0.00	0.00
Technical Knowhow				Internal Cash			
Fees & Exp.	0.00	20.00	20.00	Accruals	0.00	0.00	0.00
Franchise & Other				Long/Medium Term			
Deposits	0.00	0.00	0.00	Borrowings	0.00	546.60	546.60
Preliminary& Pre-							
operative Exp	0.00	3.00	3.00	Debentures / Bonds	0.00	0.00	0.00
Provision for				Unsecured			
Contingencies	0.00	32.00	32.00	Loans/Deposits	0.00	0.00	0.00
Margin Money -							

299.00 299.00

728.80 728.80 TOTAL



0.00

0.00

Working Capital

TOTAL

# **Project at a Glance**

Year	Annu	alised	Book Value	Debt	Dividen d		ined nings	Payout	Probable Market Price	P/E Ratio	Yield Price/ Book Value
	EDO	OFDO	D (	71	Per	Dan C	<b>V1</b>			No.of Times	
	EPS	CEPS	Per	Share	Share		Share			rimes	
	`	`			`	%	`	%	•		%
						100.0					
1-2	6.69	9.49	16.69	24.00	0.00	0	6.69	0.00	6.69	1.00	0.00
						100.0					
2-3	9.43	11.89	26.12	18.00	0.00	0	9.43	0.00	9.43	1.00	0.00
						100.0					
3-4	12.30	14.45	38.42	12.00	0.00	0	12.30	0.00	12.30	1.00	0.00
4-						100.0					
5	15.05	16.94	53.47	6.00	0.00	0	15.05	0.00	15.05	1.00	0.00
5-						100.0					
6	17.65	19.32	71.12	0.00	0.00	0	17.65	0.00	17.65	1.00	0.00



Turno

ver

Ratio

4.73

4.86

4.85

4.78

4.68

Assets Curre

nt

Ratio

1.13

1.16

1.20

1.25

1.35

Profitability Ratio

PAT

%

Net

ibutio n

Contr Ratio

1014. 8.31

991.3 6.96

1128. 6.93

1265. 6.91

1402. 6.90

16

3

38

43

48

P/V

%

%

%

%

%

%

Project a	at a G	lance
-----------	--------	-------

D. S. C. R.

ative

(Number of times)

1.40

1.55

1.73

1.91

2.11

www.entrepreneurindia.co

2.11

Cumul Over

all

Year

Initi al

1-

2

2-

3

3-

4-5

5-6

Indivi

1.40

1.72

2.12

2.57

3.09

dual

Proj	ect	at	<b>a</b>	Glance
		-		

its

Debt

3.00

1.44

0.69

0.31

0.11

0.00

(Number of

times)

3.00

1.44

0.69

0.31

0.11

0.00

Debt / Equity Total Retur

as-

Depos Equity Wort

Net

h

%

7.54

5.19

3.81

2.94

2.36

n on

Net

Wort

h

%

**GPM** 

%

PBT

%

3.19% 1.49% 1.00%

3.47% 1.87% 1.21%

3.65% 2.16% 1.38%

3.77% 2.36% 1.50%

3.84% 2.50% 1.58%

59.30%

61.47%

31.15%

86.957

2 Years 3

Months

|--|

BEP - Maximum Utilisation Year

Cash BEP (% of Installed Capacity)

Total BEP (% of Installed Capacity)

IRR, PAYBACK and FACR

Internal Rate of Return .. (In %age)

Payback Period of the Project is (In Years)

Fixed Assets Coverage Ratio (No. of times)



www.entrepreneurindia.co



# Major Queries/Questions Answered in the Report?

- 1. What is Active Pharma Ingredients (API)
  Manufacturing industry?
- 2. How has the Active Pharma Ingredients (API)
  Manufacturing industry performed so far and how
  will it perform in the coming years?
- 3. What is the Project Feasibility of Active Pharma Ingredients (API) Manufacturing Plant?
- 4. What are the requirements of Working Capital for setting up Active Pharma Ingredients (API)

  Manufacturing plant?



- 5. What is the structure of the Active Pharma Ingredients (API) Manufacturing Business and who are the key/major players?
- 6. What is the total project cost for setting up Active Pharma Ingredients (API) Manufacturing Business?
- 7. What are the operating costs for setting up Active Pharma Ingredients (API) Manufacturing plant?
- 8. What are the machinery and equipment requirements for setting up Active Pharma Ingredients (API) Manufacturing plant?



- 9. Who are the Suppliers and Manufacturers of Plant & Machinery for setting up Active Pharma Ingredients (API) Manufacturing plant?
- 10. What are the requirements of raw material for setting up Active Pharma Ingredients (API) Manufacturing plant?
- 11. Who are the Suppliers and Manufacturers of Raw materials for setting up Active Pharma Ingredients (API) Manufacturing Business?
- 12. What is the Manufacturing Process of Active Pharma Ingredients (API)?

- (npcs)
  - 13. What is the total size of land required for setting up Active Pharma Ingredients (API) Manufacturing plant?
  - 14. What will be the income and expenditures for Active Pharma Ingredients (API) Manufacturing Business?
  - 15. What are the Projected Balance Sheets of Active Pharma Ingredients (API) Manufacturing plant?
  - 16. What are the requirement of utilities and overheads for setting up Active Pharma Ingredients (API) Manufacturing plant?
  - 17. What is the Built up Area Requirement and cost for setting up Active Pharma Ingredients (API) Manufacturing Business?

- npcs
  - 18. What are the Personnel (Manpower)
    Requirements for setting up Active Pharma
    Ingredients (API) Manufacturing Business?
  - 19. What are Statistics of Import & Export for Active Pharma Ingredients (API)?
  - 20. What is the time required to break-even of Active Pharma Ingredients (API) Manufacturing Business?
  - 21. What is the Break-Even Analysis of Active Pharma Ingredients (API) Manufacturing plant?
  - 22. What are the Project financials of Active Pharma Ingredients (API) Manufacturing Business?



- 23. What are the Profitability Ratios of Active Pharma Ingredients (API) Manufacturing Project?
- 24. What is the Sensitivity Analysis-Price/Volume of Active Pharma Ingredients (API) Manufacturing plant?
- 25. What are the Projected Pay-Back Period and IRR of Active Pharma Ingredients (API) Manufacturing plant?
- 26. What is the Process Flow Sheet Diagram of Active Pharma Ingredients (API) Manufacturing project?

27. What are the Market Opportunities for setting up Active Pharma Ingredients (API)

- 28. What is the Market Study and Assessment for setting up Active Pharma Ingredients (API) Manufacturing Business?
- 29. What is the Plant Layout for setting up Active Pharma Ingredients (API) Manufacturing Business?

**Manufacturing plant?** 



# Table of Contents of the Project Report



#### 1 PROJECT LOCATION

- 1.1. DISTRICT PROFILE & GEOTECHNICAL SITE CHARACTERIZATION
- 1.1.1. General
- 1.1.2. Physical Characteristics
- 1.1.3. Climate & Rainfall
- 1.1.4. Map
- 1.1.5. Economy & Industry
- 1.1.6. Transportation and Communications

#### 2. INTRODUCTION



#### 3. AZITHROMYCIN

- 3.1. MEDICAL USES
- 3.2. CHEMICAL AND PHYSICAL DATA
- 3.3. RAW MATERIAL
- 3.4. MANUFACTURING PROCESS
- 3.5. PROCESS FLOW DIAGRAM

#### 4. CEFIXIME

- 4.1. MEDICAL USES
- 4.2. PHYSICAL PROPERTIES
- 4.3. RAW MATERIAL
- 4.4. MANUFACTURING PROCESS
- 4.5. PROCESS FLOW DIAGRAM



5.	TELMISARTAN	
5.1.	MEDICAL USES	
5.2.	CHEMICAL PROPERTIES	
5.3.	PHYSICAL PROPERTIES	
5.4.	RAW MATERIAL	
5.5.	MANUFACTURING PROCESS	
5.6.	PROCESS FLOW DIAGRAM	
6.	DICLOFENAC SODIUM	
6.1.	MEDICAL USES	
6.2.	FORMULATIONS AND TRADE NAMES	
6.3.	PROPERTIES	
6.4.	RAW MATERIALS	
6.5.	MANUFACTURING PROCESS	
6.6.	PROCESS FLOW DIAGRAM	



#### **7**. **ACECLOFENAC** 7.1. CHEMISTRY 7.2. CHEMICAL AND PHYSICAL DATA 7.3. RAW MATERIALS 7.4. MANUFACTURING PROCESS 8. PROCESS FLOW DIAGRAM 9. MARKET SURVEY 9.1. ABOUT THE GEOGRAPHY 9.2. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 9.2.1. Further Key Findings from the Study Suggest 9.2.2. **Industry Insights** 9.2.3. **Application Insights** Regional Insights 9.2.4. Market Share Insights 9.2.5.



9.3. KEY PLAYERS IN THE GLOBAL APIS MARKE'
--

9.4. SPECIALTY MEDICINES

# 9.5. KEY PLAYERS FOR GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT SERVICES MARKET REPORTS

#### 9.6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT

- 9.6.1. Market Dynamics
- 9.6.2. Regional Analysis
- 9.6.3. Drivers and Key Restraints
- 9.6.4. Market Studied By Top Companies
- 9.6.5. Market Trends

#### 9.7. INCREASING COMPETITION IN THE API MARKET

- 9.7.1. Market Segmentation
- 9.7.2. Regional Outlook
- 9.7.3. Market Dynamics
- 9.7.4. Market Segmentations
- 9.7.5. Regional Analysis

#### 9.8. MARKET KEY PLAYERS



# 10. MAJOR FIVE ACTIVE PHARMACEUTICAL INGREDIENTS COMPANIES

- 11. EXPORT & IMPORT: ALL COUNTRIES
- 11.1. EXPORT: ALL COUNTRIES
- 11.2. IMPORT: ALL COUNTRIES
- 12. FINANCIALS & COMPARISON OF MAJOR INDIAN PLAYERS/COMPANIES
- 12.1. ABOUT FINANCIAL STATEMENTS OF CMIE DATABASE
- 12.2. PROFITS & APPROPRIATIONS
- 12.3. TOTAL LIABILITIES
- 12.4. TOTAL ASSETS
- 12.5. NET CASH FLOW FROM OPERATING ACTIVITIES



#### 12.6. **SECTION -I**

- 12.6.1. Name of Company with Contact Details
- 12.6.2. Name of Director(S)
- 12.6.3. Plant Capacity
- 12.6.4. Location of Plant
- 12.6.5. Credit Ratings
- 12.6.6. Name of Raw Material(S) Consumed with Quantity &Cost

#### 12.7. SECTION-II

- 12.7.1. Assets
- 12.7.2. Cash Flow
- 12.7.3. Cost as % Ge of Sales
- 12.7.4. Forex Transaction
- 12.7.5. Growth in Assets & Liabilities
- 12.7.6. Growth in Income & Expenditure



- 12.7.7. Income & Expenditure
- 12.7.8. Liabilities
- 12.7.9. Liquidity Ratios
- 12.7.10. Profitability Ratio
- 12.7.11. Profits
- 12.7.12. Return Ratios
- 12.7.13. Structure of Assets & Liabilities(%)
- 12.7.14. Working Capital & Turnover Ratios
- 13. COMPANY PROFILE OF MAJOR PLAYERS
- 14. EXPORT & IMPORT STATISTICS OF INDIA
- 14.1. EXPORT STATISTICS ON ACTIVE PHARMACEUTICAL INGREDIENTS
- 14.2. IMPORT STATISTICS ON ACTIVE PHARMACEUTICAL INGREDIENTS



#### 15. PRESENT MANUFACTURERS

- 16. BUYER'S LIST
- 16.1. CONTACT DETAILS OF BUYER'S
- 16.2. NAME OF DIRECTOR(S)
- 16.3. PLANT CAPACITY
- 16.4. CREDIT RATINGS
- 16.5. COMPANY WISE CONSUMPTION DETAIL OF THE RAW

**MATERIALS** 

- 17. SUPPLIERS OF PLANT & MACHINERY
- 18. SUPPLIERS OF RAW MATERIAL



#### 19. PHOTOGRAPHS/IMAGES FOR REFERENCE

- 19.1. MACHINERY PHOTOGRAPHS
- 19.2. RAW MATERIAL PHOTOGRAPHS
- 19.3. PRODUCT PHOTOGRAPHS

#### 20. PLANT LAYOUT



# **Project Financials**

•	Project at a Glance	Annexure
•	Assumptions for Profitability workings	1
•	Plant Economics	2
•	Production Schedule	3
•	Land & Building	4
	Factory Land & Building Site Development Expenses	

www.niir.org

Plant 8	& Machinery5
	Indigenous Machineries
	Other Machineries (Miscellaneous, Laboratory etc.)
Other I	Fixed Assets6
	Furniture & Fixtures
	<b>Pre-operative and Preliminary Expenses</b>
	Technical Knowhow
	Provision of Contingencies
Workir	ng Capital Requirement Per Month7
	Raw Material
	Packing Material
	Lab & ETP Chemical Cost
	Consumable Store



•	Overheads Required Per Month and Per Annum
•	Salary and Wages9
•	Turnover Per Annum10
•	Share Capital11
	Equity Capital  Preference Share Capital

www.niir.org



- Annexure 1 :: Cost of Project and Means of Finance
- Annexure 2 :: Profitability and Net Cash Accruals
- Revenue/Income/Realisation
- Expenses/Cost of Products/Services/Items
- Gross Profit
- Financial Charges
- Total Cost of Sales
- Net Profit After Taxes
- Net Cash Accruals

www.niir.org



- Annexure 3 :: Assessment of Working Capital requirements
- Current Assets
- Gross Working Capital
- Current Liabilities
- Net Working Capital
- Working Note for Calculation of Work-in-process
- Annexure 4 :: Sources and Disposition of Funds

www.niir.org



- Annexure 5 :: Projected Balance Sheets
- ROI (Average of Fixed Assets)
- RONW (Average of Share Capital)
- ROI (Average of Total Assets)
- Annexure 6 :: Profitability Ratios
- D.S.C.R
- Earnings Per Share (EPS)
- Debt Equity Ratio



• Annexure 7 :: Break-Even Analysis

- Variable Cost & Expenses
- Semi-Variable/Semi-Fixed Expenses
- Profit Volume Ratio (PVR)
- Fixed Expenses / Cost
- B.E.P



• Annexure 8 to 11 :: Sensitivity Analysis-Price/Volume

- Resultant N.P.B.T
- Resultant D.S.C.R
- Resultant PV Ratio
- Resultant DER
- Resultant ROI
- Resultant BEP

www.niir.org



- Annexure 12 :: Shareholding Pattern and Stake Status
- Equity Capital
- Preference Share Capital
- Annexure 13 :: Quantitative Details-Output/Sales/Stocks
- Determined Capacity P.A of Products/Services
- Achievable Efficiency/Yield % of Products/Services/Items
- Net Usable Load/Capacity of Products/Services/Items
- Expected Sales/ Revenue/ Income of Products/ Services/
   Items



• Annexure 14 :: Product wise Domestic Sales

#### Realisation

- Annexure 15 :: Total Raw Material Cost
- Annexure 16 :: Raw Material Cost per unit
- Annexure 17 :: Total Lab & ETP Chemical Cost
- Annexure 18 :: Consumables, Store etc.
- Annexure 19 :: Packing Material Cost
- Annexure 20 :: Packing Material Cost Per Unit



•	Annexure 21	••	<b>Employees Expenses</b>
---	-------------	----	---------------------------

- Annexure 22 :: Fuel Expenses
- Annexure 23 :: Power/Electricity Expenses
- Annexure 24 :: Royalty & Other Charges
- Annexure 25 :: Repairs & Maintenance Expenses
- Annexure 26 :: Other Manufacturing Expenses
- Annexure 27 :: Administration Expenses
- Annexure 28 :: Selling Expenses



- Annexure 29 :: Depreciation Charges as per Books (Total)
- Annexure 30 :: Depreciation Charges as per Books (P & M)
- Annexure 31 :: Depreciation Charges as per IT Act WDV (Total)
- Annexure 32 :: Depreciation Charges as per IT Act WDV (P & M)
- Annexure 33 :: Interest and Repayment Term Loans
- Annexure 34 :: Tax on Profits
- Annexure 35 :: Projected Pay-Back Period and IRR



## Reasons for Buying our Report:

- This report helps you to identify a profitable project for investing or diversifying into by throwing light to crucial areas like industry size, market potential of the product and reasons for investing in the product
- This report provides vital information on the product like it's characteristics and segmentation
- This report helps you market and place the product correctly by identifying the target customer group of the product



- This report helps you understand the viability of the project by disclosing details like machinery required, project costs and snapshot of other project financials
- The report provides a glimpse of government regulations applicable on the industry
- The report provides forecasts of key parameters which helps to anticipate the industry performance and make sound business decisions



# Our Approach:

- Our research reports broadly cover Indian markets, present analysis, outlook and forecast for a period of five years.
- The market forecasts are developed on the basis of secondary research and are cross-validated through interactions with the industry players
- We use reliable sources of information and databases. And information from such sources is processed by us and included in the report

## **Scope of the Report**

www.entrepreneurindia.co

The report titled "Market Survey cum Detailed Techno Economic Feasibility Report on Active Pharma Ingredients (API)." provides an insight into Active Pharma Ingredients (API) market in India with focus on uses and applications, Manufacturing Process, Process Flow Sheets, Plant Layout and Project Financials of Active Pharma Ingredients (API) project. The report assesses the market sizing and growth of the Indian Active Pharma Ingredients (API) Industry. While expanding a current business or while venturing into new business, entrepreneurs are often faced with the dilemma of zeroing in on a suitable product/line. And before diversifying/venturing into any product, they wish to study the following aspects of the identified product:



- Good Present/Future Demand
- Export-Import Market Potential
- Raw Material & Manpower Availability
- Project Costs and Payback Period

We at NPCS, through our reliable expertise in the project consultancy and market research field, have demystified the situation by putting forward the emerging business opportunity in the Active Pharma Ingredients (API) sector in India along with its business prospects. Through this report we have identified Active Pharma Ingredients (API) project as a lucrative investment avenue.



# **Tags**

#APIBusiness #apimanufacturing #Apiproduction #APImarket #APIProject #ApiStartup #APIindustry #Activepharmaingredients #pharmaingredients #IndianPharma, #medicineingredients #CoronavirusBusiness #COVID2019 #Activepharmaingredientbusinessplan #APIbusinessplan #APIbusinessidea #startupAPIbusiness #Activepharmaingredientmanufacturing #APIproduction #APIBusinessplan #Azithromycin #Cefixime #Telmisartan #Diclofenacsodium #Acecloflenac #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #startupbusinessideas #entrepreneurindia #startupbusiness #howtostartbusiness #InvestInStartups #Plan4Business #StartupProject #ProjectReport #startupplan #BusinessKaiseshurukare #BusinessProjectReport



# NIIR PROJECT CONSULTANCY SERVICES (NPCS) can provide Detailed Project Report on

<u>Active Pharma Ingredients (API) • Azithromycin • Cefixime • Telmisartan • Diclofenac Sodium • Acecloflenac</u>

# See more

Project Reports & Profiles BOOKS

**Market Research Report** 



# Visit us at

www.entrepreneurindia.co

www.niir.org

www.niir.org



# Take a look at Niir Project Consultancy Services on #Street View

https://goo.gl/VstWkd

Locate us on

Google Maps

https://goo.gl/maps/BKkUtq9gevT2



### **OUR CLIENTS**

Our inexhaustible Client list includes public-sector companies, Corporate Houses, Government undertaking, individual entrepreneurs, NRI, Foreign investors, non-profit organizations and educational institutions from all parts of the World. The list is just a glimpse of our esteemed & satisfied Clients.

Click here to take a look <a href="https://goo.gl/G3ICjV">https://goo.gl/G3ICjV</a>

www.niir.org



#### Select and Choose the Right Business Startup for You

#### (Instant Online Project Identification and Selection)

Finding the right startup business is one of the most popular subject today. Starting a business is no easy endeavor, but the time, effort, and challenges can be worth it if you succeed. To give yourself the best chance to be successful, take your time to carefully find the right business for you. We, at NPCS, endeavor to make business selection a simple and convenient step for any entrepreneur/startup. Our expert team, by capitalizing on its dexterity and decade's long experience in the field, has created a list of profitable ventures for entrepreneurs who wish to diversify or venture. The list so mentioned is updated regularly to give you a regular dose of new emerging opportunities.

**Visit:** <a href="https://www.entrepreneurindia.co/project-identification">https://www.entrepreneurindia.co/project-identification</a>



#### **Download Complete List of Project Reports:**

#### Detailed Project Reports

Visit:- <a href="https://www.entrepreneurindia.co/complete-project-list">https://www.entrepreneurindia.co/complete-project-list</a>

NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our Market Survey cum Detailed Techno Economic Feasibility Report provides an insight of market in India. The report assesses the market sizing and growth of the Industry. While expanding a current business or while venturing into new business, entrepreneurs are often faced with the dilemma of zeroing in on a suitable product/line.



And before diversifying/venturing into any product, they wish to study the following aspects of the identified product:

- Good Present/Future Demand
- Export-Import Market Potential
- Raw Material & Manpower Availability
- Project Costs and Payback Period

The detailed project report covers all aspect of business, from analyzing the market, confirming availability of various necessities such as Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities, Cost and Revenue, Plant Economics, Production Schedule,



Working Capital Requirement, uses and applications, Plant Layout, Project Financials, Process Flow Sheet, Cost of Project, Projected Balance Sheets, Profitability Ratios, Break Even Analysis. The DPR (Detailed Project Report) is formulated by highly accomplished and experienced consultants and the market research and analysis are supported by a panel of experts and digitalized data bank.

We at NPCS, through our reliable expertise in the project consultancy and market research field, have demystified the situation by putting forward the emerging business opportunity in India along with its business prospects.....Read more

www.niir.org



## Contact us

#### NIIR PROJECT CONSULTANCY SERVICES

106-E, Kamla Nagar, Opp. Mall ST,

New Delhi-110007, India.

Email: <u>npcs.ei@gmail.com</u>, <u>info@entrepreneurindia.co</u>

Tel: +91-11-23843955, 23845654, 23845886

Mobile: +91-9097075054, 8800733955

Fax: +91-11-23845886

Website: www.entrepreneurindia.co, www.niir.org

Take a look at NIIR PROJECT CONSULTANCY SERVICES on #StreetView

https://goo.gl/VstWkd



# NIIR PROJECT CONSULTANCY SERVICES

AN ISO 9001: 2015 CERTIFIED COMPANY

www.niir.org

www.entrepreneurindia.co



#### Who are we?

- One of the leading reliable names in industrial world for providing the most comprehensive technical consulting services
- We adopt a systematic approach to provide the strong fundamental support needed for the effective delivery of services to our Clients' in India & abroad



We at NPCS want to grow with you by providing solutions scale to suit your new operations and help you reduce risk and give a high return on application investments. We have successfully achieved top-notch quality standards with a high level of customer appreciation resulting in long lasting relation and large amount of referral work through technological breakthrough and innovative concepts. A large number of our Indian, Overseas and NRI Clients have appreciated our expertise for excellence which speaks volumes about our commitment and dedication to every client's success.



We bring deep, functional expertise, but are known for our holistic perspective: we capture value across boundaries and between the silos of any organization. We have proven a multiplier effect from optimizing the sum of the parts, not just the individual pieces. We actively encourage a culture of innovation, which facilitates the development of new technologies and ensures a high quality product.





#### What do we offer?

- Project Identification
- Detailed Project Reports/Pre-feasibility Reports
- Market Research Reports
- Business Plan
- Technology Books and Directory
- Industry Trend
- Databases on CD-ROM
- Laboratory Testing Services
- Turnkey Project Consultancy/Solutions
- Entrepreneur India (An Industrial Monthly Journal)




## How are we different?

- We have two decades long experience in project consultancy and market research field
- We empower our customers with the prerequisite know-how to take sound business decisions
- We help catalyze business growth by providing distinctive and profound market analysis
- We serve a wide array of customers, from individual entrepreneurs to Corporations and Foreign Investors
- We use authentic & reliable sources to ensure business precision



## Our Approach





#### Who do we Serve?

- Public-sector Companies
- Corporates
- Government Undertakings
- Individual Entrepreneurs
- o NRI's
- Foreign Investors
- o Non-profit Organizations, NBFC's
- Educational Institutions
- Embassies & Consulates
- Consultancies
- Industry / trade associations



#### **Sectors We Cover**

- o Ayurvedic And Herbal Medicines, Herbal Cosmetics
- o Alcoholic And Non Alcoholic Beverages, Drinks
- Adhesives, Industrial Adhesive, Sealants, Glues,
   Gum & Resin
- Activated Carbon & Activated Charcoal
- Aluminium And Aluminium Extrusion Profiles & Sections,
- Bio-fertilizers And Biotechnology
- Breakfast Snacks And Cereal Food
- Bicycle Tyres & Tubes, Bicycle Parts, Bicycle Assembling



#### Sectors We Cover Cont.

- Bamboo And Cane Based Projects
- Building Materials And Construction Projects
- o Biodegradable & Bioplastic Based Projects
- Chemicals (Organic And Inorganic)
- Confectionery, Bakery/Baking And Other Food
- Cereal Processing
- Coconut And Coconut Based Products
- Cold Storage For Fruits & Vegetables
- Coal & Coal Byproduct



#### Sectors We Cover Cont...

- Copper & Copper Based Projects
- Dairy/Milk Processing
- Disinfectants, Pesticides, Insecticides, Mosquito Repellents,
- Electrical, Electronic And Computer based Projects
- o Essential Oils, Oils & Fats And Allied
- Engineering Goods
- Fibre Glass & Float Glass
- Fast Moving Consumer Goods
- o Food, Bakery, Agro Processing



#### Sectors We Cover cont...

- Fruits & Vegetables Processing
- Ferro Alloys Based Projects
- Fertilizers & Biofertilizers
- Ginger & Ginger Based Projects
- Herbs And Medicinal Cultivation And Jatropha (Biofuel)
- Hotel & Hospitability Projects
- Hospital Based Projects
- Herbal Based Projects
- o Inks, Stationery And Export Industries



#### **Sectors We Cover**

Cont...

- Infrastructure Projects
- Jute & Jute Based Products
- Leather And Leather Based Projects
- Leisure & Entertainment Based Projects
- Livestock Farming Of Birds & Animals
- Minerals And Minerals
- Maize Processing(Wet Milling) & Maize Based Projects
- Medical Plastics, Disposables Plastic Syringe, Blood Bags
- o Organic Farming, Neem Products Etc.



#### Sectors We Cover cont...

- o Paints, Pigments, Varnish & Lacquer
- Paper And Paper Board, Paper Recycling Projects
- Printing Inks
- Packaging Based Projects
- Perfumes, Cosmetics And Flavours
- Power Generation Based Projects & Renewable Energy Based Projects
- Pharmaceuticals And Drugs
- Plantations, Farming And Cultivations
- o Plastic Film, Plastic Waste And Plastic Compounds
- o Plastic, PVC, PET, HDPE, LDPE Etc.



#### Sectors We Cover Cont...

- Potato And Potato Based Projects
- Printing And Packaging
- Real Estate, Leisure And Hospitality
- Rubber And Rubber Products
- Soaps And Detergents
- Stationary Products
- Spices And Snacks Food
- Steel & Steel Products
- Textile Auxiliary And Chemicals



#### Sectors We Cover Cont...

- Township & Residential Complex
- Textiles And Readymade Garments
- Waste Management & Recycling
- Wood & Wood Products
- Water Industry(Packaged Drinking Water & Mineral Water)
- Wire & Cable



## MARKET RESEARCH REPORTS

www.niir.org



## **Objective**

- №To get a detailed scenario of the industry along with its structure and classification
- №To provide a comprehensive analysis of the industry by covering aspects like:
  - Someth drivers of the industry

     Compare the ind
  - Latest market trends
  - ⊗Insights on regulatory framework
  - **SWOT** Analysis
  - ⊗Demand-Supply Situation
  - ⊗Foreign Trade
  - ⊗Porters 5 Forces Analysis



## **Objective**

- ™To provide forecasts of key parameters which helps to
  anticipate the industry performance
- ™To help chart growth trajectory of a business by detailing
  the factors that affect the industry growth
- №To help an entrepreneur/manager in keeping abreast with the changes in the industry
- ⊗To evaluate the competitive landscape of the industry by detailing:
  - ⊗Key players with their market shares
  - >> Financial comparison of present players



## **Clientele**

- ⊗Venturist/Capitalists
- ⊗Entrepreneur/Companies
- **∞**Investment Funds
- ∞Foreign Investors, NRI's
- Project Consultants/Chartered Accountants
- **∞**Banks
- **∞**Corporates

Click here for list



## **Data Sources**

Secondary Research

Online Research<br/>Industry Journals

Surveys
One-on-one
Interactions
Databases

Primary Research

> Industry Sources

Industry Experts
Industry
Associations
Companies







### **Our Team**

©Our research team comprises of experts from various financial fields:

∞MBA's

Industry Researchers

⊗Financial Planners

research veterans with decades of experience

www.niir.org



## Structure of the Report

- •1. Overview
- •2. Market Analysis
  - 2.1Growth Drivers
  - □2.2Emerging Trends in the Industry
  - □2.3Regulatory Framework
  - $\square 2.4$ SWOT Analysis
  - □2.5Herfindahl–Hirschman Index (HHI)
- •3. Market Forecasts
- •4. Key Players



## Structure of the Report

Cont

- ≥5. Key Financials and Analysis
- ≈5.1 Contact Information
- ≈5.2 Key Financials
- ≈5.3 Financial comparison
- №6. Industry Size & Outlook

www.niir.org www.entrepreneurindia.co



## Take a look at Niir Project Consultancy Services on #Street View

https://goo.gl/VstWkd

www.niir.org

www.entrepreneurindia.co



## Contact us

## NIIR PROJECT CONSULTANCY SERVICES

106-E, Kamla Nagar, Opp. Mall ST,

New Delhi-110007, India.

Email: <u>npcs.ei@gmail.com</u>, <u>info@entrepreneurindia.co</u>

Tel: +91-11-23843955, 23845654, 23845886

Mobile: +91-9097075054, 8800733955

Fax: +91-11-23845886

Website: <u>www.entrepreneurindia.co</u>, <u>www.niir.org</u>

Take a look at NIIR PROJECT CONSULTANCY SERVICES on #StreetView

https://goo.gl/VstWkd



## Follow us



> https://www.linkedin.com/company/niir-project-consultancy-services



>https://www.facebook.com/NIIR.ORG



>https://www.youtube.com/user/NIIRproject



>https://twitter.com/npcs\_in



https://www.pinterest.com/npcsindia/





For more information, visit us at:

<a href="https://www.niir.org">www.niir.org</a>
<a href="https://www.entrepreneurindia.co">www.entrepreneurindia.co</a>

www.niir.org

www.entrepreneurindia.co